FindTrial
Sign In

Association of COVID-19 severity with blood group antigens.

Study to explore association of COVID-19 disease severity with clinically significant blood group antigenic constitution. - BG-CoV

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/08/027471
Enrollment
200
Registered
2020-08-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

None listed

Sponsors

AIIMS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Written informed consent to participate in the study. 2.Confirmed SARS CoV-2 infection; 3.Adults (Age range: 18-64 years).

Exclusion criteria

Exclusion criteria: 1.Failure to obtain Written informed consent; 2.Known history of any transfusions in the last 3 months; 3.Children (Age range: Birth â?? 17 years) and Older adults (Age range: > 65 years).

Design outcomes

Primary

MeasureTime frame
Establishing a relation between COVID-19 patients of symptomatology and blood group antigenic constitution. b) Exploring a predictive tool for COVID-19 in association with blood group antigenic constitution and patientâ??s clinical parameters which may be validated in further studies.Timepoint: 12 months—

Secondary

MeasureTime frame
To explore a possible prediction tool for assessment of COVID-19 severity in relation to blood group antigens, age, weight, gender, co-morbid conditions, symptomatology, hematological and bio-chemical parameters.Timepoint: 12 months—

Countries

India

Contacts

Public ContactDiptiranjan Rout

AIIMS

drdiptiranjanrout@gmail.com08727804293

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026